Ricevi le ultime notizie sulle azioni Aytu BioPharma con aggiornamenti su tendenze di mercato, dati finanziari e analisi di Benzinga. Rimani informato sulle performance di AYTU

Ultime notizie per

Aytu BioPharma

Aytu BioPharma Inc

AN2 Therapeutics

Athira Pharma

Cingulate

Clearside Biomedical, Inc. - Common Stock

Clearside Biomedical

Cumberland Pharmaceuticals Inc. - Common Stock

Cumberland

Citius Pharmaceuticals, Inc. - Common Stock

Citius Pharmaceuticals

Curanex Pharmaceuticals Inc - Common Stock

Curanex Pharmaceuticals

Cadrenal Therapeutics, Inc. - Common Stock

Cadrenal Therapeutics

Dare Bioscience

Evoke Pharma

Hoth Therapeutics

IGC Pharma

Iterum Therapeutics

Lexaria Bioscience

Lipocine

MIRA Pharmaceuticals, Inc. - Common Stock

Mira Pharmaceuticals

NewcelX

Processa Pharmaceuticals, Inc. - Common Stock

Processa Pharmaceuticals

Pulmatrix

Quantum Biopharma Ltd. - Class B Subordinate Voting Shares

Quantum BioPharma

SCYNEXIS

SenesTech

Traws Pharma

TherapeuticsMD

Verrica Pharmaceuticals Inc. - Common Stock

Verrica Pharmaceuticals

Aytu BioPharma (AYTU) Previsione

Notizie

Utili

Valutazioni degli analisti

Insider trading

Vendite allo scoperto

Rapporto azionario

Aytu BioPharma Inc is a specialty pharmaceutical company with a commercial portfolio of prescription therapeutics and consumer health products. The company's primary prescription products treat attention deficit hyperactivity disorder and other common pediatric conditions. It is building a complementary therapeutic development pipeline, including a prospective treatment (AR101/enzastaurin) for vascular Ehlers-Danlos Syndrome, a rare genetic disease resulting in high morbidity and a significantly shortened lifespan. The company operates one business segment consisting of various prescription pharmaceutical products sold through third parties.

Comments

Aytu BioPharma Notizie sulle azioni

Notizie

Ultime notizie per

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO